2 research outputs found
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΡΠΎΡΡΠΎΠ΄ΠΈΡΡΡΠ΅ΡΠ°Π·Ρ-4 ΡΠΎΡΠ»ΡΠΌΠΈΠ»Π°ΡΡΠ° (ΠΠ°ΠΊΡΠ°Ρ) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ
The aim of this studyΒ was to evaluate clinical efficacy and safety of selective phosphodiesterase"4 inhibitor roflumilast in patients with COPD and metabolic syndrome.Methods. In this prospective study, patients with stage III β IV COPD, frequent exacerbation phenotype (β₯ 2 per a year) andΒ metabolic syndrome (n = 42) were treated with roflumilast (Daxas) 500 mg q.d. additionally to the basic therapy for 12 months. Clinical investigation, mMRC scale and CAT questionnaire, pulse oxymetry, spirometry, 6"min walking test, measurement of glucose, lipids and C"reactive proteinΒ in blood were used in all patients.Results. Exacerbation rate decreased in patients with COPD treated with roflumilast. FEV1 and quality of lifeΒ improved in patients treated with roflumilast. Therapy with roflumilast was associated with statistically significant reduction in the waist circumference without significant change in the body weight, waist"to"hip ratio or body mass index.Conclusion. Therapy with roflumilast was associated withΒ improvement in clinical, laboratory and functional parameters and reduction in exacerbation rate in patients with COPD and metabolic syndrome.Π¦Π΅Π»Ρ. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠΎΡΠ»ΡΠΌΠΈΠ»Π°ΡΡ (ΠΠ°ΠΊΡΠ°Ρ) Π² Π΄ΠΎΠ·Π΅ 500 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ (ΠΠ‘) Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΌ ΠΊΠΎΠ½ΡΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΏΡΠΈ ΠΠΠ£Π Β«ΠΠ±Π»Π°ΡΡΠ½Π°Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»ΡΠ½ΠΈΡΠ° β 4Β» (Π§Π΅Π»ΡΠ±ΠΈΠ½ΡΠΊ) ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ"ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΠ»Π°Β (n = 42) Ρ Π₯ΠΠΠ IIIβIV ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΠΠ‘ ΠΈ ΡΠ°ΡΡΡΠΌΠΈ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ Π₯ΠΠΠ (β₯ 2 ΡΠ°Π· Π² Π³ΠΎΠ΄).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΎΡΠ»ΡΠΌΠΈΠ»Π°ΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΠΈ ΠΠ‘ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ°ΡΡΠΎΡΡ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Π₯ΠΠΠ